In a clinical trial by Carsulo et al., durvalumab (anti-PD-L1) demonstrated an 18% overall response rate (ORR) and 8% complete response rate (CRR) in diffuse large B-cell lymphoma and a 59% ORR and 27% CRR in follicular lymphoma. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.